-
Article
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
In patients with low-risk polycythemia vera, exposure to low-dose Ropeginterferon alfa-2b (Ropeg) 100 µg every 2 weeks for 2 years was more effective than the standard treatment of therapeutic phlebotomy in ma...
-
Chapter and Conference Paper
Hyperbolic Techniques in Epidemiological Modeling
We present a class of models devoted to the spreading of a virus, inspired by the recent pandemics. Key features are the ability to comprehend age structure, spatial movements, social distancing policies and t...
-
Living Reference Work Entry In depth
Women and Medieval Universities
Women could not attend university in the Middle Ages, so how were they connected to these institutions of higher education? By considering the networks that formed and intertwined with university life, women c...
-
Article
Open AccessDeterminants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
-
Chapter
Surgery
The chapter introduces dermatologists to dermatologic surgery. The basic concepts, stitches, and techniques are explained; this allows a correct approach to the milestone of the dermatologic surgeon: the fusif...
-
Article
Overview and progress on the Laser Interferometer Space Antenna mission
At a Lorentz Center workshop, Chiara Caprini, Antoine Petiteau and Elena Maria Rossi gave a series of presentations about the Laser Interferometer Space Antenna (LISA) mission, the instrument, and the associat...
-
Article
Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group
Ruxolitinib is approved for polycythemia vera (PV) patients after failure to previous cytoreductive therapy, based on durable results observed in phase 3 trials. We report a multicenter retrospective study dem...
-
Article
Open AccessNeutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
We investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictor of thrombosis in polycythemia vera (PV). After a median follow-up of 2.51 years, of 1508 PV patients enrolled in the ECLAP study, 82 and ...
-
Article
Open AccessJAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
Arterial (AT) and venous (VT) thrombotic events are the most common complications in patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality. In this regard, the impact of JAK2V...
-
Article
Methane oxidation of residual landfill gas in a full-scale biofilter: human health risk assessment of volatile and malodours compound emissions
A human health risk assessment was performed to evaluate if a biofilter for the biological methane oxidation reduces the risk from exposure to landfill gas emissions and improves the air quality mitigating odo...
-
Article
Open AccessAn age and space structured SIR model describing the Covid-19 pandemic
We present an epidemic model capable of describing key features of the Covid-19 pandemic. While capturing several qualitative properties of the virus spreading, it allows to compute the basic reproduction numb...
-
Article
Extracellular matrix deposition by adipose-derived stem cells and fibroblasts: a comparative study
Cell-based strategies are today widely studied as possible therapies for wound healing. In this setting, fibroblasts play a key role since they are the main dermal cellular component and are responsible for ex...
-
Article
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT
-
Article
Open AccessTracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
The management of patients with myelofibrosis (MF) has dramatically changed since the introduction of ruxolitinib as a tailored treatment strategy. However, the perceptions about the use of this drug in clinic...
-
Chapter
Budd–Chiari Syndrome and Myeloproliferative Neoplasms
Non-cirrhotic and non-malignant splanchnic vein thrombosis (SVT) recognizes Philadelphia-negative myeloproliferative neoplasms (MPN) as the most frequent systemic cause. An overt MPN is diagnosed in 40% of the...
-
Article
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis
Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms. During treatment, as rare conditions, leukocytosis and/or thrombocyto...
-
Article
Open AccessIndications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis?
-
Article
Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation
The purpose of this study was to determine retrospectively, through a single-center evaluation, whether FDG PET-CT normalized semi-quantitative parameters may predict response to induction chemotherapy (iChT) and...
-
Article
Open AccessHydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
We collected 1500 patients with myeloproliferative neoplasms (MPN) and arterial or venous thrombosis (935/565), pooling three independent cohorts previously reported. Long-term treatment with antiplatelet drug...
-
Article
Seismic analysis and retrofit of the oldest R/C elevated water tank in Florence
The seismic performance of an elevated water tower with reinforced concrete staging structure—the oldest one in Florence—is analyzed in this paper. The tower, erected in 1905, is a major achievement by enginee...
